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Notch 1/2 genes play tumor-suppressing functions in squamous cell carcinoma (SCC), a
very common malignancy in skin and internal organs. In contrast with Notch, we show that
the transcription factor CSL (also known as RBP-Jk), a key effector of canonical Notch
signaling endowed with intrinsic transcription-repressive functions, plays a tumor-promoting
function in SCC development. Expression of this gene decreased in upper epidermal layers
and human keratinocytes (HKCs) undergoing differentiation, while it increased in
premalignant and malignant SCC lesions from skin, head/neck, and lung. Increased CSL
levels enhanced the proliferative potential of HKCs and SCC cells, while silencing of CSL
induced growth arrest and apoptosis. In vivo, SCC cells with increased CSL levels gave
rise to rapidly expanding tumors, while cells with silenced CSL formed smaller and more
differentiated tumors with enhanced inflammatory infiltrate. Global transcriptomic analysis of
HKCs and SCC cells with silenced CSL revealed major modulation of apoptotic, cell-cycle,
and proinflammatory genes. We also show that the histone demethylase KDM6B is a direct
CSL-negative target, with inverse roles of CSL in HKC and SCC proliferative capacity,
tumorigenesis, and tumor-associated inflammatory reaction. CSL/KDM6B protein
expression could be used as a biomarker of SCC development and indicator of cancer
treatment.
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Introduction
Squamous cell carcinomas (SCCs) are the most common forms 
of human cancer (1) and are a major cause of death. These het-
erogeneous tumors originate from surface epithelia, such as skin 
and aerodigestive and urogenital tracts, in response to a variety 
of noxious conditions (1). Common gene alterations are found in 
these tumors, distinguishable in 2 main categories: mutations with 
driver function in many cancer types and more selective muta-
tions affecting squamous cell–fate commitment and/or ensuing 
terminal differentiation (1).
Notch signaling is an important form of direct cell-cell com-
munication with an essential role in the switch between prolifera-
tion and differentiation of keratinocytes (2). It impinges on direct 
regulators of proliferative potential, such as p21WAF1/Cip1 (3) and 
p63 (4), as well as more indirect paracrine mechanisms involved in 
normal skin homeostasis and barrier function (5–7). This pathway 
plays a similarly important role in oral (8), esophageal (9), bron-
chial (10), and cervical epithelia (11).
Inactivating mutations of NOTCH1, NOTCH2, and NOTCH3 
receptor genes are frequently found in SCCs from various body sites 
(1). Of these, NOTCH1 plays a prominent role in SCC suppression. 
In addition to being frequently mutated, this gene is a direct positive 
target of p53 in keratinocytes and is commonly downmodulated as 
a consequence of compromised p53 function in SCC cells (12, 13).
In spite of its highly context-dependent functions, “canonical” 
Notch signaling has been highly conserved throughout evolution, 
with translocation of activated Notch intracellular domain into the 
nucleus, converting the DNA-binding protein CSL (RBP-Jκ) from 
a repressor into an activator of transcription (14). While function-
ing as an essential mediator of Notch activation, CSL is endowed 
with intrinsic transcription-repressive function and can be convert-
ed by other cofactors, besides NOTCH, into an activator (15, 16). 
Evidence from various genetic models indicates that abrogation of 
CSL function can have consequences beyond suppression of Notch 
signaling, while conversely, NOTCH activation may involve other 
mediators besides CSL (15, 16). In skin, the more pronounced phe-
notype of mice with keratinocyte-specific deletion of NOTCH1 and 
NOTCH2 genes versus CSL suggests that NOTCH has a broader 
function than CSL (17). However, the converse possibility that CSL 
also plays a role distinct from that of NOTCH in keratinocytes and 
SCC development has not yet been addressed.
Epigenetic regulators impinge on the balance between cancer 
cell renewal and commitment to differentiation (18). The cumula-
tive mutation rate of this family of genes in SCCs is more than 50%, 
with a number of them involved in a squamous differentiation pro-
gram (1). Trimethylation of histone H3 at lysine 27 (H3K27me3) 
is a key histone modification, with transcription-repressive func-
tion that is deregulated in a variety of cancers (19). Removal of 
H3K27me2 and H3K27me3 marks by the KDM6B (JMJD3) demeth-
ylase can operate in concert with NOTCH activation in cancer 
development, as indicated by the shared prooncogenic role of the 
2 genes in T cell acute lymphoblastic leukemia (T-ALL) cells (20). 
Like NOTCH, KDM6B is involved in key cellular processes, such as 
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tinocytes (HKCs), expression of the CSL protein was substantially 
reduced with induction of differentiation by high-confluency con-
ditions or suspension culture at times when a terminal differentia-
tion marker such as involucrin was induced (Figure 2A and Supple-
mental Figure 1D). Downmodulation of CSL protein levels upon 
differentiation was likely due to a posttranscriptional mechanism, 
as CSL mRNA levels were increased rather than decreased (Figure 
2B and Supplemental Figure 1E).
Relative to HKCs, CSL protein levels were increased in a panel 
of skin and oral SCC cell lines, independently of p53 status (The 
TP53 Web Site, http://p53.free.fr) (42) (Figure 2C). mRNA levels 
were also higher in most of the tested cancer cell lines, indicating 
that CSL expression can be deregulated at both transcriptional 
and posttranscriptional levels (Figure 2D). A similar increase in 
CSL protein levels, with less consistent upregulation of mRNA 
levels, was also found in a panel of lung SCC cells relative to pri-
mary human bronchial epithelial cells (HBECs) (Figure 2, E and 
F). Upregulation of CSL expression in SCC13 cells versus HKCs 
was also detected by immunohistochemical staining of these cells 
brought into suspension, using the same fixation and staining pro-
cedures utilized in the clinic for analysis of cytological specimens 
(Supplemental Figure 1F).
CSL is a positive regulator of keratinocyte and SCC proliferative 
potential. To assess biological significance of the above findings, we 
evaluated consequences of modulated CSL expression in HKCs. 
Three independent strains were stably infected with a retrovirus 
expressing myc-tagged CSL, which in several previous papers was 
shown to be functionally equivalent to untagged CSL (43, 44). A 
several-fold increase of CSL levels (Figure 3A), approximating that 
in SCC cells, resulted in significantly enhanced proliferative activ-
ity, as assessed by an assay for metabolically active cells (CellTiter-
Glo) (Figure 3B). Clonogenicity assays provide a well-established 
method to assess the fraction of keratinocytes with elevated pro-
liferative potential (putative stem cells) (45). Paralleling previous 
results, increased CSL expression significantly enhanced the frac-
tion of HKCs with clonogenic capacities (Figure 3C).
Conversely, overall proliferation of HKCs was strongly sup-
pressed by shRNA-mediated CSL gene silencing (Figure 3, D and E), 
associated with reduction of their clonogenic potential (Figure 3F). 
The sphere-forming capability of cells embedded in Matrigel was 
used as an additional measure of the proliferative potential of cells 
(46). Strong inhibitory effects were also observed with this assay 
upon CSL silencing in all tested HKC strains (Figure 3G). Decreased 
proliferative potential of HKCs was paralleled by decreased DNA 
synthesis, as assessed by EdU labeling of cells (Figure 3H).
Like HKCs, SCC cell lines contain subpopulations with ele-
vated proliferative potential (putative cancer stem cells), which 
can be assessed by clonogenicity assays (47). Lentivirus-mediated 
increase of CSL expression significantly enhanced colony- and 
sphere-forming capability of a panel of SCC cell lines (Figure 
4, A–C), while conversely, CSL gene silencing inhibited clono-
genic potential and reduced overall proliferation (Figure 4, D–F). 
Growth inhibitory effects of CSL gene silencing were not due 
to specific toxic mechanisms, as they were not observed with 
SCCO28 cells (Figure 4, D–F), an oral SCC-derived cell line with 
advanced features of epithelial-to-mesenchymal transformation 
(48). The sphere-forming capability of various SCC cell lines in 
cell-cycle control, senescence, and differentiation, and may play a 
role in cancer development in a context-dependent manner (21–
23). In fact, KDM6B expression is upregulated in several malignan-
cies, such as Hodgkin’s lymphoma (24), breast cancer (25), gliomas 
(26), melanoma (27), and renal cell carcinoma (28), while it is sup-
pressed in others, including lung adenocarcinoma and squamous 
cell carcinoma (29), colon cancer (30, 31), and liver and pancreatic 
cancers (32). While inactivating KDM6B gene mutations are only 
found in 1%–3% of SCCs (cBioPortal for Cancer Genomics; http://
www.cbioportal.org), the gene, like NOTCH1, has been implicated 
as a positive determinant of squamous cell differentiation (33).
Increased immune cell infiltration into tumors is a posi-
tive prognostic sign for elimination of cancer cells and favorable 
response to cancer immunotherapy (34). In cells of the immune/
inflammatory systems, a crosstalk has been uncovered between 
KDM6B and NF-KB and STAT family members through a variety 
of mechanisms, including physical association (35–38). In con-
trast, mechanisms involved in the control of KDM6B in keratino-
cytes and SCC and possible interconnection with NOTCH/CSL 
signaling have not been investigated.
We report here that, in contrast with NOTCH activation, CSL 
has an intrinsic tumor-promoting function in SCC development 
that is mediated, in part, by suppression of KDM6B expression, 
a direct CSL target. Compared with CSL, KDM6B has an inverse 
effect on HKC and SCC proliferative capacity, tumorigenesis, and 
tumor-associated inflammatory reaction, and the 2 proteins could 
be used as prognostic markers of SCC development.
Results
CSL gene expression is reduced in differentiating keratinocytes and 
induced in premalignant and malignant cancer cells. CSL can play 
biologically significant roles as a repressor of transcription inde-
pendently of NOTCH activation (15). Control of CSL function in 
this context can occur through modulation of its expression (39, 
40). In human skin, immunofluorescence analysis showed that 
CSL is highly expressed in keratinocytes of lower epidermal lay-
ers, while it is substantially downmodulated in upper layers (Figure 
1A and Supplemental Figure 1A; supplemental material available 
online with this article; https://doi.org/10.1172/JCI96915DS1), in 
contrast with the opposite pattern of NOTCH 1/2 expression that 
we previously reported (41). Similarly elevated CSL expression 
was also found in lower layers of oral epithelium, with pronounced 
downmodulation in upper layers (Figure 1B).
Actinic keratoses (AK) are premalignant SCC precursor lesions 
associated with an altered squamous cell differentiation program 
and expansion of cells of the proliferative compartment. Immu-
nohistochemical analysis of these lesions showed pronounced 
upregulation of CSL expression relative to the surrounding nor-
mal epidermis (Figure 1C and Supplemental Figure 1B). Upregu-
lated CSL expression was also found in dysplastic versus normal 
epithelium of the oral cavity, with a further increase in adjacent 
SCCs (Figure 1D and Supplemental Figure 1C). In parallel, immu-
nohistochemical analysis of tissue arrays of skin and oral SCCs 
showed significantly greater CSL signal intensity in high- versus 
low-grade tumors (Figure 1E).
These findings were mirrored by a pattern of CSL expression 
in cultured cells. In 3 independent strains of primary human kera-
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in immune-compromised mice (40). CSL-overexpressing SCC 
cells formed rapidly expanding tumors, and mice were sacrificed 
at early times, in most cases prior to tumor formation by control 
cells injected in parallel (Figure 5A). Conversely, tumor formation 
by SCC cells was substantially delayed by CSL silencing and even 
in some cases totally suppressed (Figure 5B). Decreased tumor 
formation was mirrored by decreased cellular proliferation, as 
Matrigel suspension was also suppressed by CSL silencing (Figure 
4G), and decreased proliferation of SCC cells could be explained 
by decreased DNA synthesis as well as enhanced apoptosis (Sup-
plemental Figure 2, A and B).
CSL promotes SCC tumor formation in a xenograft model. We 
next assessed the effects of CSL modulation on the tumorigenic 
potential of SCC cells utilizing an orthotopic ear-injection assay 
Figure 1. Higher CSL expression in 
premalignant and malignant squamous 
cancer lesions. (A) Immunofluorescence 
analysis of CSL expression in epider-
mis of normal skin, with DAPI staining 
for cell identification. Similar analysis 
of normal skin samples from 2 more 
individuals is shown in Supplemental 
Figure 1A. n = 3 individuals. Scale bar: 25 
μm. (B) Immunohistochemical analysis 
of CSL expression in normal oral epi-
thelium. n = 1 individual. Scale bar: 125 
μm. Dotted lines mark the border of the 
epidermal compartment relative to the 
underlying mesenchyme. (C) Immuno-
histochemical analysis of CSL expression 
in an AK (54) lesion and flanking normal 
(N) skin. Similar analysis of additional 
AK lesions and flanking skin is shown 
in Supplemental Figure 1B. n = 5 AK 
regions; n = 5 N regions. Right panel: CSL 
signal quantification of all AK patients. 
Data are shown as mean ± SEM, 2-tailed 
paired t test. Scale bars: 1000 μm 
(upper panels); 100 μm (lower panels). 
(D) Immunohistochemical analysis of 
CSL expression in oral SCC lesions and 
flanking dysplastic and normal tissue. 
For additional lesions, see Supplemen-
tal Figure 1C. n = 7 carcinoma; n = 4 
dysplastic; n = 7 normal regions. Right 
panel: CSL signal quantification of all 
SCC patients. Data are shown as mean 
± SEM, 1-way ANOVA with Dunnett’s 
test. Scale bars: 1000 μm (upper panels); 
100 μm (lower panels). (E) Immunohis-
tochemical analysis of CSL expression 
in tissue arrays of skin and oral SCC 
lesions in low- versus high-grade tumors 
(defined by invasion beyond submuco-
sal tissue). Representative images are 
shown along with CSL signal quantifica-
tion. Data are shown as mean ± SEM, 
2-tailed unpaired t test. n = 8 low-grade 
skin lesions; n = 12 high-grade skin 
lesions; n = 18 low-grade oral lesions;  
n = 8 high-grade oral lesions. Scale  
bars: 200 μm. (C–E) **P < 0.005;  
***P < 0.0005.
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NOTCH1 and differentiation signature genes in HKCs (4), fur-
ther consistent with a NOTCH separate function of CSL in these 
cells (Table 3 and Supplemental Table 2). In contrast, there was 
significant correlation between CSL-modulated genes and gene 
signatures of pathways implicated in inhibition of keratinocyte 
proliferation (specifically NF-κB and TGF-B) and inflammation 
(Figure 7A and Table 3).
Similar RNA-seq analysis was carried out in SCC13 cells with 
CSL gene silencing (GEO GSE102762). As with HKCs, many 
genes were deregulated upon CSL silencing in SCC13 cells, with 
a few hundred that were similarly modulated in both (Figure 7B). 
There was also high concordance in GO analysis, which showed 
that mitosis and DNA replication genes were among those down-
regulated by CSL silencing in SCC13 cells and that apoptosis 
genes were among those upregulated in response to CSL silenc-
ing (Tables 1 and 2, and Supplemental Table 1). GSEA also showed 
a similar positive correlation between the expression profiles of 
SCC13 cells with CSL gene silencing and gene signatures related 
to TGF-B, NF-κB, TNF-A, INF, and inflammatory responses, while 
there was again no significant association with NOTCH or kera-
tinocyte differentiation gene signatures (Table 3 and Supplemen-
tal Table 2). Quantitative reverse-transcriptase PCR (RT-qPCR) 
assessed by Ki67 positivity (Figure 6A), and enhanced differentia-
tion, as assessed by keratin 1 (K1) and K10 expression (Figure 6, B 
and C). Importantly, despite the lack of intrinsic effects on the pro-
liferation of SCCO28 cells, CSL silencing also suppressed tumori-
genicity of these cells, with decreased Ki67 positivity (Figure 5B 
and Figure 6A). The decreased tumorigenicity was accompanied 
in all cases by enhanced infiltration of immune cells together with 
a marked increase in expression of the proinflammatory cytokine 
IL6 (Supplemental Figure 3, A and B).
CSL acts as a shared determinant of gene expression in HKCs 
and SCC cells. Independently of NOTCH activation, CSL plays a 
constitutive repressive function in gene transcription. By RNA-
sequencing (RNA-seq) analysis, more than 1,000 genes were 
consistently up- or downregulated in HKCs by CSL gene silencing 
(NCBI’s Gene Expression Omnibus database; GEO GSE102762). 
Gene ontology (GO) analysis showed that gene families most sig-
nificantly upregulated by CSL silencing are related to apoptosis 
and regulation of programmed cell death, while those most signif-
icantly downregulated are related to mitosis and DNA replication 
and repair (Tables 1 and 2 and Supplemental Table 1). By gene set 
enrichment analysis (GSEA) (49), we found no significant corre-
lation between CSL-modulated genes and previously established 
Figure 2. Higher CSL expression in proliferating vs. differentiating keratinocytes and squamous cancer cells. (A) Immunoblot analysis of CSL expres-
sion in HKCs under proliferating (50% and 70% confluence [cf]) versus differentiating culture conditions (7 days at 100% cf; 48 hours in suspension 
culture [susp]). Immunoblot was sequentially probed with antibodies against CSL, involucrin (IVL) (80), and actin. Numbers refer to relative folds of CSL 
expression using actin for normalization. Results of similar experiment with 2 other HKC strains are shown in Supplemental Figure 1D. (B) HKCs as in A 
were analyzed by RT-qPCR for CSL and involucrin mRNA expression with 36B4 for normalization. Similar analysis of 2 additional HKC strains is shown 
in Supplemental Figure 1E. (C) Immunoblot analysis of CSL expression in HKCs under proliferating conditions versus panel of skin and oral SCC cell lines. 
CSL protein on immunoblot can be variously detected as a single or dual band, probably reflecting different phosphorylation states, with no correlation to 
p53 status of cells. Immunoblot was sequentially probed with antibodies against CSL, actin, and p53. Right panel: quantification of relative levels of CSL 
expression of this and 2 other immunoblots, using actin for normalization. (D) Cells as in C were analyzed by RT-qPCR for CSL mRNA expression with 36B4 
for normalization. (E) Lung SCC cell lines were analyzed in parallel with HBECs for levels of CSL or p53 expression utilizing tubulin as equal loading control. 
Right panel: quantification of relative levels of CSL expression of this and 2 other immunoblots. (F) Cells as in E were analyzed by RT-qPCR for CSL mRNA 
expression with 36B4 for normalization. (C–F) Data are shown as mean ± SEM. *P < 0.05; **P < 0.005; ***P < 0.0005, 1-way ANOVA with Dunnett’s test.  
n = 3 independent experiments.
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GSE102762). In striking contrast to HKCs and SCC13 cells, only 
36 genes were upregulated in SCCO28 cells upon CSL silencing 
and 4 were downmodulated. These genes belonged to families 
related to membrane/signaling, enzymes, extracellular matrix, 
and inflammatory/immunomodulatory cytokines, but none were 
directly involved in cell division control or apoptosis (Figure 7F 
and Supplemental Table 1).
analysis confirmed downregulation of the panel of cell-cycle regu-
latory genes and upregulation of apoptotic and proinflammatory 
genes in HKCs and SCC13 cells as well as other SCC cells upon 
CSL silencing (Figure 7, C–E).
To probe into the consequences of CSL gene silencing in can-
cer cells that are resistant to its growth-inhibitory effects, simi-
lar RNA-seq analysis was carried out with SCCO28 cells (GEO 
Figure 3. Positive role of CSL in promoting keratinocyte proliferative potential and cell survival. (A) HKCs infected with retroviral vector for constitutive 
Myc-tagged CSL expression (mycCSL) in parallel with vector control (pmx), were analyzed for CSL expression by immunoblotting. Numbers refer to relative 
folds of CSL expression using GAPDH for normalization. (B) Three independent HKC strains, infected as in A, were tested for cell metabolic activity assays. 
Results are presented as luminescence intensity values relative to day 1. (C) The same HKC strains as in B were plated at limited density, and colony 
formation was measured. (D) HKCs infected with 2 shRNA lentiviruses against CSL (shCSL1 and shCSL2) versus empty control (PLKO1) were analyzed for 
CSL expression by immunoblotting. (E) Three HKC strains infected as in D were tested for cell metabolic assays. Lower luminescence/metabolic activity 
rates of control cells in panel B versus E are likely due to the use of cells with higher passage number in B, which was necessary because of lower efficiency 
of infection with PMX vectors used for those experiments. (F) The same HKC strains as in E assessed for colony formation. (G) The same HKC strains as 
in E were plated in Matrigel suspension cultures. The number of spheroids was counted using ImageJ software (NIH). Shown are representative images of 
spheroids formed by 1 HKC strain together with quantification of 3 strains. Scale bars: 250 μm. (H) The same HKC strains as in E were labeled with EdU for 
6 hours. EdU-positive cells were counted using ImageJ software. Shown are representative images of cells of 1 HKC strain together with quantification of 
3 strains. Scale bars: 100 μm. (B and C) Data are shown as mean ± SD, 2-tailed unpaired t test. n = 3 biological replicates/strain. (E–H) Data are shown as 
mean ± SD. *P < 0.05; **P < 0.005; ***P < 0.0005, 1-way ANOVA with Dunnett’s test. n = 3 biological replicates/strain.
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IL6 was among the proinflammatory cytokines upregulated in 
SCC13, SCCO22, and SCCO28 cells with silenced CSL, consistent 
with increased IL6 expression found in small tumors formed by 
these cells by ear injection (Supplemental Figure 3B). However, this 
could be a secondary event, as tumor formation by these assays took 
a relatively long time and, in a number of cases, cells with silenced 
CSL yielded no detectable tumors. An important question was 
therefore whether increased expression of IL6 and other coregu-
lated cytokines occurs in SCC cells with silenced CSL even in vivo 
at early times preceding drastic differences in tumor formation. To 
Figure 4. Positive role of CSL in promoting proliferative potential of skin, oral, and lung SCC cells. (A) Cell lines derived from skin (SCC13), oral (FaDu), 
and lung (H520) SCCs stably infected with lentiviral vector for inducible Myc-tagged CSL versus empty vector control (pIND20) were analyzed 2 days after 
doxycycline treatment for CSL expression by immunoblotting. Numbers refer to relative folds of CSL expression using actin for normalization. (B) The 
same SCC cells as in A were plated at a limited density, and colony formation was measured. (C) The same SCC cells as in B were plated in Matrigel suspen-
sion. Number and size of spheroids were assessed using ImageJ software. (D) Cell lines derived from skin (SCC12, SCC13), oral (SCCO22, SCCO28, and FaDu), 
and lung (H520 and H2170) SCCs infected with 2 shRNA lentiviruses against CSL were analyzed for CSL expression by immunoblotting. (E) The same SCC 
cells as in D were plated at a limited density, and colony formation was measured. (F) The same SCC cells as in E were tested for cell metabolic activity 
assays. (G) The same SCC cells as in E were plated in Matrigel suspension. Shown are representative images of spheroids formed by FaDu cells. Scale bars: 
250 μm. (B and C) Data are shown as mean ± SEM, 2-tailed unpaired t test. n = 3 independent experiments. (E–G) Data are shown as mean ± SEM.  
*P < 0.05; **P < 0.005; ***P < 0.0005, 1-way ANOVA with Dunnett’s test. n = 3 independent experiments.
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address this point, we resorted to an alternative skin tumorigenicity 
assay, based on intradermal injection of cells embedded in Matrigel.
Matrigel nodules form immediately after injection into ani-
mals and can be easily retrieved at any time. Parallel injections of 
SCC13 and SCCO28 cells with or without CSL gene silencing were 
used for these assays. Matrigel nodules retrieved at 1 week had 
sizes comparable to those of SCC cells with or without CSL silenc-
ing, with more detectable differences starting to occur at 2 weeks 
(Figure 8A). Histological features and inflammation, as detected by 
pan-keratin and CD45 staining, respectively, were comparable in 
all cases (Supplemental Figure 4, A and B). To assess intrinsic dif-
ferences in gene expression, we resorted to laser capture microdis-
section (LCM) of pan-keratin–positive SCC cells, followed by RT-
qPCR analysis. Results showed significant upregulation of IL6 and 
CCL20, a leukocyte chemotactic cytokine under positive IL6 con-
trol (50), in SCC13 and SCCO28 cells, with silenced CSL at both 1 
and 2 weeks, with less consistent differences for 2 other cytokines, 
IL1-A and CXCL1 (Figure 8, B and C).
Similar intradermal tumorigenicity assays were performed 
with SCC13 cells with increased CSL expression via lentiviral vec-
tor infection. At 2 weeks after injection, Matrigel nodules harbor-
ing SCC cells with increased CSL expression exhibited a notably 
larger size than controls (Figure 8D), in agreement with previous 
results obtained by ear-injection assays. Histological features and 
inflammation were also comparable in all cases (Supplemental 
Figure 4, C and D). LCM and RT-qPCR analysis at both 1 and 2 
weeks revealed significant reduction of IL6 and CCL20 expres-
sion in SCC cells with increased CSL, mirroring the inverse effects 
of CSL gene silencing (Figure 8E). Differences in expression of 
IL1-A and CXCL1 were again less consistent (Figure 8E).
Figure 5. Tumor modulatory effects of increased versus suppressed CSL expression on SCC cells. (A) SCC13 and FaDu cells stably infected with lentiviral 
vector for doxycycline-inducible Myc-tagged CSL or empty vector control (pIND20) were injected in parallel into ears of NOD/SCID mice. Shown are tumor 
volumes at day of sacrifice (left panel), with representative images for 1 pair of mouse ears (right panel) and corresponding H&E staining of SCC13 lesions. 
n = 7 mice for SCC13 lesions; n = 4 mice for FaDu lesions. (B) SCC13, SCCO22, and SCCO28 cells infected with CSL-silencing lentivirus versus empty vector 
control were injected into ears of NOD/SCID mice. Shown are tumor volumes (upper panels) with representative images of 1 pair of mouse ears (lower 
panels), and corresponding H&E staining of SCCO22 lesions (right panels). Scale bars: 250 μm. n = 6 mice for SCC13 lesions; n = 6 mice for SCCO22 lesions;  
n = 6 mice for SCCO28 lesions from experiment 1 (Exp.1) and 5 mice from experiment 2. (A and B) Scale bars: 250 μm. Data are shown as mean ± SEM.  
*P < 0.05; ***P < 0.0005, 1-tailed paired t test.
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sites of the KDM6B locus (Figure 9C) and to the HES1 promoter as 
a positive control (Figure 9D). Upregulation of the KDM6B gene 
by CSL gene silencing was confirmed by RT-qPCR in HKCs and 
SCC cells analyzed in this study, including SCCO28 cells (Figure 
10, A and B). Upregulation of the KDM6B protein was also found 
by immunofluorescence analysis of HKCs and SCC cells with 
silenced CSL (Figure 10C). Even in vivo, in intradermal Matrigel 
assays described above, KDM6B expression was pronouncedly 
upregulated in SCC13 and SCC028 cells with silenced CSL (Figure 
10D). Conversely, KDM6B expression was found to be downregu-
lated by LCM and RT-qPCR analysis of AK and SCC lesions versus 
flanking normal epidermis (Figure 10E).
To assess functional significance of KDM6B upregulation, 
HKCs were infected with retroviral vectors overexpressing 
KDM6B in WT versus demethylase-defective mutant forms (33) 
in parallel with empty vector control. Expression of function-
ally active KDM6B, but not the inactive form, was sufficient to 
KDM6B as direct target and mediator of CSL regulatory func-
tion in keratinocyte/SCC proliferation and tumorigenesis. For fur-
ther mechanistic insights, we sought to identify direct CSL tar-
gets whose upregulation by CSL gene silencing could impinge 
on cell proliferation and tumor formation. Out of several hun-
dreds of CSL target genes identified by ChIP-seq analysis (GEO 
GSE102761) (Supplemental Table 3), 68 were found by RNA-seq 
to be significantly upregulated by silencing of the gene in HKCs 
(Figure 9A). These coded for enzymes involved in signal transduc-
tion and metabolism, secreted factors, and cell surface and cyto-
skeletal proteins as well as transcription factors and chromatin 
modifiers (Figure 9B). Out of these genes, 13 were also upregu-
lated by CSL silencing in SCC13 cells, including HES1, a “canoni-
cal” NOTCH/CSL target variously implicated in keratinocytes (4, 
51–53), and KDM6B, a histone H3-K27 demethylase with context-
dependent functions in cancer development (22) (Figure 9B). 
Direct ChIP assays on HKCs confirmed CSL binding to multiple 
Figure 6. Decreased proliferation and increased differentiation in tumors formed by SCC cells with CSL gene silencing. (A) Double-immunofluorescence 
analysis of proliferation (Ki67) and epithelial (pan-keratin) markers in ear lesions formed by SCC13, SCCO22, and SCCO28 cells with CSL gene silencing. 
Shown are representative images as well as quantification of Ki67-positive nuclei in keratin-positive regions using ImageJ software. (B and C) Double-
immunofluorescence analysis with antibodies against the K1 and K10 differentiation markers versus total keratins (pan-keratin) of ear lesions formed by 
SCC13 and SCCO22 cells with CSL gene silencing. Shown are representative images as well as quantification of K1 and K10 in pan-keratin–positive regions 
using ImageJ software. (A–C) Scale bars: 150 μm. Data are shown as mean ± SEM. n = 4 mice for SCC13 lesions; n = 4 mice for SCCO22 lesions; n = 5 mice for 
SCCO28 lesions. *P < 0.05; **P < 0.005, 1-tailed paired t test.
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CSL and KDM6B compared with CSL silencing alone, with signifi-
cant increases in the fraction of cancer cells positive for prolifera-
tion marker Ki67 (Figure 12B). Enhanced tumor formation by dual 
CSL and KDM6B gene silencing was accompanied by decreased 
expression of IL6 and reduced recruitment of inflammatory cells, 
reversing the effects of CSL gene-silencing alone (Figure 12, C and 
D, to be compared with Supplemental Figure 3, A and B).
Thus, KDM6B is a direct CSL-negative target with an inverse 
opposite role in control of HKC and SCC proliferative capacity, 
tumorigenesis, and tumor-associated inflammatory reaction.
Discussion
Proliferation and differentiation of squamous epithelial cells are 
tightly regulated through integrated signaling networks, with 
NOTCH activation as a critical player (1, 2). We show here that, 
besides its role as a mediator of NOTCH activation, CSL has 
another and opposite function in SCC development. In contrast to 
NOTCH, CSL levels are inversely correlated with keratinocyte dif-
ferentiation and are already upregulated at premalignant stages of 
skin and oral SCC development. This is of functional significance, 
as increased CSL expression enhances keratinocyte and SCC pro-
liferation potential and tumor formation, while CSL downmodula-
tion suppresses them.
reproduce the inhibitory effects of CSL silencing on cellular pro-
liferation and colony formation in 3 different HKC strains (Fig-
ure 11, A and B). Conversely, silencing of KDM6B counteracted 
growth-inhibitory effects of CSL knockdown in SCC13 and, to 
a lesser extent, in SCCO22 cells (Figure 11C). Overall colony-
forming capability was increased in cells with dual silencing of 
CSL and KDM6B genes relative to cells with CSL silencing alone 
(Figure 11D), with particular increases in colonies of larger size, 
thought to originate from cells with greater proliferative capac-
ity (45) (Figure 11E).
At the gene-expression level, counteracting effects were 
detected upon concomitant silencing of CSL and KDM6B on key 
cell-cycle and proinflammatory genes (such as CCNB1, CDK1, and 
IL6), with no effects on others (such as CCND1, CASP8, or BID) 
(Figure 11F), pointing to KDM6B as a main, but not the only, medi-
ator of CSL-silencing effects on gene transcription.
A key question was to what extent KDM6B upregulation is 
involved in the tumor suppression that CSL silencing exerts in 
vivo. Accordingly, 3 different SCC cell lines (SCC13, SCCO22, and 
SCCO28) with shRNA-mediated silencing of CSL individually and 
in combination with KDM6B knockdown were injected into ears 
of immune-compromised mice. As shown in Figure 12A, the size 
of cancer lesions was dramatically enhanced by dual silencing of 
Table 1. GO analysis of upregulated genes by RNA-seq analysis of HKCs and SCC13 cells upon CSL gene silencing
Upregulated upon CSL silencing HKC SCC13
GO term P value Adjusted P value P value Adjusted P value
GO:0042981, regulation of apoptosis 1.43 × 10–06 5.35 × 10–04 4.18 × 10–06 8.22 × 10–04
GO:0043067, regulation of programmed cell death 2.21 × 10–06 6.90 × 10–04 5.99 × 10–06 9.64 × 10–04
GO:0001944, vasculature development 5.20 × 10–05 0.010785 3.88 × 10–06 8.57 × 10–04
GO:0006464, protein modification process 3.16 × 10–04 0.036405 0.010404 0.182356
GO:0009966, regulation of signal transduction 5.23 × 10–04 0.056092 3.48 × 10–13 6.17 × 10–10
GO:0022604, regulation of cell morphogenesis 0.001617 0.114317 3.75 × 10–07 1.66 × 10–04
GO:0007243, protein kinase cascade 0.001776 0.120358 2.74 × 10–06 6.92 × 10–04
GO:0007242, intracellular signaling cascade 0.002385 0.138661 1.33 × 10–07 7.85 × 10–05
GO:0007264, small GTPase-mediated signal transduction 0.004627 0.195421 0.006576 7.47 × 10–04
GO:0008285, negative regulation of cell proliferation 0.016505 0.400453 0.017633 0.249064
  
Table 2. GO analysis of downregulated genes identified by RNA-seq analysis of HKC and SCC13 cells upon CSL gene silencing
Downregulated upon CSL silencing HKC SCC13
GO Term P value Adjusted P value P value Adjusted P value
GO:0007067, mitosis 7.30 × 10–58 3.65 × 10–55 1.56 × 10–11 3.81 × 10–09
GO:0000087, M phase of mitotic cell cycle 5.70 × 10–57 2.14 × 10–54 4.53 × 10–12 1.39 × 10–09
GO:0006260, DNA replication 5.29 × 10–48 1.59 × 10–45 7.83 × 10–11 1.37 × 10–08
GO:0006281, DNA repair 1.06 × 10–38 2.65 × 10–36 1.42 × 10–05 0.001082
GO:0007051, spindle organization 3.46 × 10–24 7.41 × 10–22 0.00207 0.100212
GO:0000075, cell-cycle checkpoint 3.56 × 10–17 6.67 × 10–15 1.58 × 10–05 0.001136
GO:0010564, regulation of cell-cycle process 8.06 × 10–11 8.06 × 10–09 3.44 × 10–05 0.002211
GO:0007346, regulation of mitotic cell cycle 3.82 × 10–10 2.86 × 10–08 1.82 × 10–04 0.011059
GO:0051783, regulation of nuclear division 1.78 × 10–04 0.006051 0.02541 0.418925
GO:0010824, regulation of centrosome duplication 0.00451 0.093734 0.01231 0.308999
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While increased CSL expres-
sion enhanced the proliferative 
potential of primary HKCs and 
various SCC cell lines, its silenc-
ing exerted opposite effects. 
Growth-inhibitory effects of CSL 
gene silencing can be explained by 
downregulation of positive regu-
lators of the cell cycle, consistent 
with the thinner epidermis and 
reduced proliferation previously 
reported in mice with keratino-
cyte-specific deletion of the CSL 
gene (53). The further widespread 
alterations in the skin of these 
mice were attributed to skin bar-
rier defects associated with strong 
induction of thymic stromal lym-
phopoietin (TSLP) cytokine production (7, 58). TSLP deregulation 
may be a peculiarity of the murine system, as it was not observed 
in human primary keratinocytes and SCC cell lines upon CSL 
gene silencing. Nevertheless, other cytokines and chemokines 
with potent proinflammatory function were instead consistently 
induced, particularly IL6, a pleiotropic regulator of the immune 
and inflammatory systems (59) that has cell-autonomous growth-
inhibitory function (59, 60), and CCL20, a leukocyte chemotactic 
factor under positive IL6 control (50). Importantly, expression of 
these cytokines was enhanced in all SCC cells with CSL silencing 
and also in vivo, in an early assay of SCC development preceding 
differences in tumor size and inflammation. As such, expression 
of these cytokines is an intrinsic rather than a secondary event of 
decreased CSL expression in SCC cells. This can have a pleiotro-
py of functions at early versus late stages of tumor development, 
when substantially increased inflammatory reaction was found in 
association with tumor suppression. An increased immune-cell 
infiltration into tumors is a sign of a favorable response to check-
point inhibitors (34), and it will be interesting to assess whether 
the regulatory network that we have uncovered correlates with 
immune infiltration in SCCs and/or their response to therapy.
Consequences of changes in CSL levels can be ascribed, 
in part, to direct negative control of the histone demethylase 
KDM6B gene, which impinges on genes with key cell-cycle– 
regulatory and proinflammatory functions (23). This gene is 
essential for life after birth, as knockout mice are born smaller 
and die perinatally due to respiratory failure (21, 61, 62). Previ-
ous studies have pointed to a potential tumor-suppressive role 
of KDM6B in specific tissues (such as lung, colon, and pancreas) 
(30–32, 63), while in others (such as blood, breast, and brain) it 
may play an opposite tumor-promoting function (24–26). This 
demethylase is an important player at the intersection between 
cellular senescence and cancer (22, 29), and it also positively reg-
ulates epidermal differentiation (33). Interestingly, the KDM6B 
gene is located on chromosome 17 in close vicinity to the p53 
tumor-suppressor gene, with allelic loss at this position occurring 
in a variety of cancers, including SCCs (1, 22, 64–66).
A number of direct CSL target genes commonly upregulated 
by its silencing in HKCs and SCC13 cells could be involved in the 
In Drosophila, it has long been known that the role of Su(H) 
(CSL homologue) as mediator of NOTCH activation cannot explain 
the different phenotypes resulting from loss of either gene (14–16). 
Increasing evidence indicates that, also in mammalian systems, 
CSL and NOTCH play only partially overlapping functions. In 
specific contexts, such as in conversion of stromal fibroblasts into 
cancer-associated fibroblasts (CAFs), loss or downmodulation of 
CSL, rather than recapitulating loss of NOTCH effects, can trigger 
the same response as NOTCH activation (40).
The possibility of distinct roles of CSL and NOTCH in can-
cer cells has been investigated to a very limited extent, with 
apparently conflicting results. A recent study focused on breast 
cancer and Burkitt lymphoma, in which NOTCH acts as an onco-
gene, pointed to an opposite tumor-suppressive role for CSL (54). 
Specifically, CSL silencing in MDA-MB-231 human breast can-
cer and DG75 Burkitt lymphoma cells enhanced tumor growth, 
with c-MYC– and NF-KB–dependent increases in cell survival. 
However, an opposite conclusion was suggested by other studies 
with cultured cancer cell lines, including one that was also with 
MDA-MB-231 cells (55–57). Thus, the possibility of distinct roles 
of NOTCH and CSL in specific cancer types needs further assess-
ment in the context of their cells of origin and tumor microen-
vironment. The present work represents such an attempt, as it 
relates to primary keratinocytes and SCC.
We have found that in normal skin and oral epithelia, CSL 
expression is inversely related to differentiation. Complex post-
transcriptional mechanisms are likely involved, at least in dif-
ferentiating primary keratinocytes in which downmodulation 
of CSL protein levels was associated with increased (rather than 
decreased) mRNA expression. Perturbed differentiation is a 
key feature of squamous cancer development (1). Consistently, 
increased CSL levels were already found in premalignant skin 
and oral SCC lesions and SCC cells. While parallel increases 
of CSL mRNA and protein levels were detected in some SCC 
cells, in others, only the protein was upregulated. Posttranscrip-
tional control of CSL expression and function is a complex and 
poorly understood topic currently under investigation. Here, we 
focused on the functional significance of changes in CSL levels in 
skin and head and neck epithelial cells.
Table 3. GSEA of differentially expressed genes in HKC and SCC13 cells upon CSL  
gene silencing
Genes modulated upon CSL silencing HKC SCC13
Gene sets AS FDR q value AS FDR q value
NGUYEN_NOTCH1_TARGETS_UP –0.557 1 –0.396 0.953
GO_KERATINOCYTE_DIFFERENTIATION –0.373 0.856 –0.337 0.966
TGFB_UP.V1_UP 0.693 0 0.7 0
HINATA_NFKB_TARGETS_ KERATINOCYTE_UP 0.709 0.01 0.697 0.011
HALLMARK_TNFA_SIGNALING_ VIA_NFKB 0.738 0 0.721 0
HALLMARK_INTERFERON_ GAMMA_RESPONSE 0.81 0 0.526 0.048
HALLMARK_INFLAMMATORY_ RESPONSE 0.688 0 0.565 0.014
HALLMARK_IL6_JAK_STAT3_ SIGNALING 0.705 0.001 0.659 0.007
HALLMARK_APOPTOSIS 0.548 0.029 0.515 0.065
AS, association score.
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of KDM6B by NF-KB and STATs observed in other cell types (36, 
38, 70, 72, 73) may also apply to squamous cancer, which is often 
associated with and can be induced by inflammation (74).
Targeting epigenetic regulators is emerging as promising can-
cer therapy. Pharmacological inhibitors of KDM6B (such as GSK-
J4) (75) were shown to inhibit growth of different cancer cell lines, 
such as T-ALL and glioma (20, 21, 76, 77), in which KDM6B plays 
an oncogenic role (22). While use of these compounds would obvi-
ously be contraindicated for squamous cancer, other drugs enhanc-
ing KDM6B function or inhibiting epigenetic modifying enzymes 
with an opposite role could be of benefit and open novel windows 
of opportunity for both prevention and treatment of this disease.
More generally, our findings could lead to valuable prognostic 
tools to be used, in combination with other markers, in the clinic. 
This is suggested by a significant association between increased 
CSL expression and high-grade SCCs in tissue microarrays (Fig-
ure 1E) and detectable differences in expression of this protein in 
normal keratinocytes versus SCC cells processed as for analysis 
observed biological effects. Among these, KDM6B was the only 
epigenetic regulator with potential global impact on gene tran-
scription. KDM6B upregulation is of functional relevance, as its 
silencing counteracted growth-inhibitory effects of CSL knock-
down in SCC cells, both in vitro and in vivo. Mechanistically, this 
could be explained by the previously reported role of KDM6B in 
direct transcriptional control of cell-cycle–inhibitory genes, such 
as CDKN2A (22, 29), differentiation genes, such as K1 (33), and 
cytokines with proinflammatory functions, specifically IL6 (35, 
37). Consistent with the latter mechanism of action, we found that 
upregulation of IL6 expression by CSL silencing was suppressed 
by concomitant KDM6B knockdown, which parallels its in vivo 
effects in rescuing tumor formation.
There are several possible mechanisms by which KDM6B can 
regulate the above genes. KDM6B can directly associate with key 
transcription factors, such as p53 (67, 68), p65, and p50 NF-KB 
subunits (37) and STAT (69, 70) and SMAD (71) family members, 
enhancing their functions. In turn, a reciprocal mode of regulation 
Figure 7. RNA-seq analysis of normal HKCs and SCC cells upon CSL silencing. (A) Representative plot of gene distribution in HKCs upon CSL silencing 
against an experimental gene set of NF-κB targets from GSEA shown in Table 3. (B) Venn diagram illustrating number of up- and downregulated genes 
overlapping in RNA-seq profiles of HKCs and SCC13 cells upon CSL silencing. (C) Three independent HKC strains infected with 2 shRNA lentiviruses against 
CSL were analyzed by RT-qPCR for indicated genes with 36B4 for normalization. n = 3 HKC strains. (D) SCC13 cells infected with 2 shRNA lentiviruses 
against CSL were analyzed by RT-qPCR for indicated genes using 36B4 for normalization. n = 3 independent experiments. Data are shown as mean ± SEM. 
(E) Panel of SCC cell lines infected with 2 shRNA lentiviruses against CSL were analyzed by RT-qPCR for indicated genes using 36B4 for normalization.  
n = 3 independent experiments. Data are shown as mean ± SEM. (F) List of genes upregulated by RNA-seq analysis in SCCO28 cells upon CSL gene silenc-
ing divided by biological function. ECM, extracellular matrix; TF, transcription factors. (C–E) *P < 0.05; **P < 0.005; ***P < 0.0005, 2-tailed 1-sample t test 
followed by Benjamini-Hochberg correction.
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Methods
Cells and human samples. Normal epithelial cells and SCC cells were 
cultured as previously described (12, 78). Oral SCC cells (SCCO11, 
SCCO13, SCCO22, and SCCO28) were provided by James Rocco (Mas-
sachusetts General Hospital, Boston, Massachusetts, USA). Oral SCC 
cells (Cal27, Cal33, and FaDu) were provided by Genrich Tolstonog 
of cytological specimens. Similar assessment of KDM6B expres-
sion in clinical settings should also be possible with development 
of adequate antibodies. These are worthwhile goals, as there is an 
unmet need for biomarkers that help identify precancerous and 
cancerous squamous cancer lesions and predict their response to 
novel modalities of treatment.
Figure 8. Effect of CSL modulation on inflammatory cytokines in vivo. (A) SCC13 and SCCO28 cells infected with CSL-silencing lentivirus versus empty 
vector control were injected into backs of NOD/SCID mice. Shown are a representative image of 1 mouse (left panel) and nodule volumes at weeks 1 and 2 
after injection (right panel). (B) Representative images of nodule sections processed for fluorescence-guided LCM utilizing anti–pan-keratin–Alexa Fluor 
488–conjugated antibody. Shown is a stained section before UV cutting (upper panel) and captured material on an LCM cap after UV cutting (lower panel). 
Scale bars: 150 μm (upper panel); 500 μm (lower panel). (C) RNA samples from LCM-captured material were examined by RT-qPCR for cytokine marker 
expression. n = 4 mice for SCC13 at week 1; n = 5 mice for SCC13 at week 2; n = 5 mice for SCCO28 at week 1; n = 4 mice for SCCO28 at week 2. (D) SCC13 cells 
stably infected with lentiviral vector for doxycycline-inducible Myc-tagged CSL or empty vector control (pIND20) were injected into backs of NOD/SCID 
mice. Shown is a representative image of 1 mouse (left panel) and nodule volumes at weeks 1 and 2 after injection (right panel). (E) RNA samples from 
LCM-captured material were examined by RT-qPCR for cytokine marker expression. n = 5 mice at week 1; n = 5 mice at week 2. (C and E) Data are shown as 
mean ± SEM. *P < 0.1; ***P < 0.001, 1-tailed 1-sample t test followed by Benjamini-Hochberg correction.
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mids and our plasmid of interest using Jetpei (Polyplus) transfection 
reagent for 6 hours, followed by virus collection after 48 hours. HKCs 
and SCC cells were infected for 1 hour and 6 hours, respectively, with 
high-titer lenti- and retroviruses sufficient to infect the majority of 
cells. Two days after infection, cells were selected with 1 μg/ml of 
puromycin for 3 days for shCSL and MSCV-KDM6B, with 500 μg/ml 
of G418 for 4 days for pmx-mycCSL and pIND20-mycCSL, and with 
10 μg/ml of blasticidin for 4 days for shKDM6B.
Lentiviral vectors encoding shRNA against KDM6B were pur-
chased from OriGene (HC141378B and HC141378C). Retroviral vec-
tors encoding WT and mutant KDM6B (MSCV-KDM6B) (Addgene 
plasmid nos. 21212 and 21214) were a gift from Paul Khavari (Stan-
ford University, Stanford, California, USA). Plasmids encoding for 
shCSL, pMXs-myc-CSL, and pINDUCER-20-myc-CSL have been 
previously described (40).
Cell assays. For proliferation assays, cell viability was assessed 
using the CellTiter-Glo Kit (Promega) by luminescence intensity 
determination over time. In brief, cells were plated onto 96-well plates 
(1,000 cells/well; triplicate wells/condition) 5 days after infection for 
shCSL and MSCV-KDM6B, 6 days after infection for pMXs-myc-CSL 
and shKDM6B, and 2 days after doxycycline treatment (500 ng/ml) for 
pIND20-mycCSL. Equal volumes of CellTiter-Glo reagent (50 μl) and 
(CHUV). Skin SCC cells (SCC12 and SCC13) were provided by James 
Rheinwald (Brigham and Women’s Hospital, Boston, Massachusetts, 
USA). Lung SCC cells (H520, H2170, HCC95, SW900, and SK-MES-1) 
were provided by Peter Hammerman (Dana-Farber Cancer Institute, 
Boston, Massachusetts, USA). HBECs were purchased from ATCC. 
HKC cells were prepared from discarded human foreskin samples 
from circumcision at the Department of Pediatrics (CHUV). In brief, 
skin tissue was immersed in 1% Dispase II (Roche) overnight at 4°C, 
and the epidermis compartment was separated from the dermis. Then, 
epidermis was minced and digested by 0.25% Trypsin-EDTA (Gibco, 
Thermo Fisher Scientific) for 1 hour at 4°C with gentle agitation, fol-
lowed by filtering through 40 μm mesh. After enzymatic digestion was 
terminated by adding a volume of serum-containing media that was 
equal to the volume of the reaction, cell pellets were collected by cen-
trifugation, plated, and cultured as previously described (41). Excised 
human AK samples not used for histological analysis were provided 
by Renato Panizzon, and human SCC samples were provided by Mas-
simo Bongiovanni. Human SCC tissue arrays were purchased from US 
Biomax (SK2081 and OR802).
Cell manipulations and plasmid constructs. Conditions for cultur-
ing cells and viral infections were as previously reported (12, 40, 78). 
Briefly, HEK293 cells were cotransfected with viral packaging plas-
Figure 9. KDM6B as a direct target of CSL. (A) Venn diagram illustrating overlap between number of genes bound by CSL (ChIP-seq profile) and those 
upregulated by silencing of the gene (RNA-seq profile) in HKCs. (B) List of overlapping genes grouped by biological function. Highlighted are direct CSL tar-
get genes commonly upregulated by CSL gene silencing in HKCs and SCC13 cells. (C) Upper panel: graphic illustration of the position of CSL-binding peaks 
revealed by Chip-seq analysis for the KDM6B gene, utilizing ENCODE information for promoter and enhancer localization, as indicated by islands of histone 
H3 modifications (K4me3 and K27Ac) along with position of the transcription start site (TSS) (81) and coding exons (boxes). Also indicated are positions of 
sites tested by direct ChIP assays. Lower panel: ChIP assays for independent confirmation of Chip-seq results of CSL binding to the indicated sites within 
the KDM6B genomic locus. HKCs were processed for ChIP assays with anti-CSL antibodies versus nonimmune IgG controls, using tagmentation for signal 
amplification (see Methods). Shown are CSL fold enrichments relative to nonimmune controls (NB, nonbinding). (D) The same ChIP samples as in C were 
tested for CSL fold enrichment of predicted segments of the HES1 gene-promoter region as positive controls for the assay.
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polymerize. Cells were brought into suspension in normal culture medi-
um plus 1% Matrigel and plated for 8 days onto a precoated chamber.
For EdU assays, DNA synthesis was assessed using the Click-iT 
Plus EdU Imaging Kit (Life Technologies). Cells were incubated for 
6 hours with 10 μM EdU-labeling solution in prewarmed tissue cul-
ture medium. Cells were then fixed with 4% formaldehyde, followed 
by permeabilization with 0.5% Triton-X 100. After permeabilization, 
cells were incubated with Click-iT Plus Reaction Cocktail for 30 min-
utes at RT, followed by counterstaining with DAPI.
For apoptosis assays, dead and preapoptotic cells were assessed 
using the Aqua Vivid Kit (Invitrogen) and the Annexin Kit (BD Biosci-
cell culture medium (50 μl) were added to cells, followed by induced 
cell lysis on an orbital shaker for 3 minutes. The plate was incubated at 
room temperature (RT) for 10 minutes, after which luminescence was 
recorded using the Molecular Device Spectra Max Fluorometer.
For clonogenicity assays, cells were plated on 60 mm dishes 
(1,000 cells/well; triplicate wells/condition) and cultured for 10 
days. Colonies were fixed with 4% formaldehyde and stained with 
1% crystal violet.
For spheroid assays, cells were plated onto 8-well chamber slides 
coated with Matrigel (BD Biosciences). In brief, 8-well chambers were 
coated with 50 μl Matrigel per well and incubated for 30 minutes to 
Figure 10. KDM6B expression increases in 
HKCs and SCC cells with CSL gene silenc-
ing and decreases in neoplastic lesions. (A) 
Three independent HKC strains infected with 2 
shRNA lentiviruses against CSL were analyzed 
by RT-qPCR for KDM6B mRNA expression with 
36B4 for normalization; 2-tailed 1-sample t test. 
n = 3 HKC strains. (B) Indicated SCC cell lines 
infected with 2 shRNA lentiviruses against CSL 
were analyzed by RT-qPCR for KDM6B mRNA 
expression with 36B4 for normalization. Data 
are shown as mean ± SEM, 2-tailed 1-sample t 
test. n = 3 independent experiments. (C) Immu-
nofluorescence analysis of KDM6B expression 
in HKCs and SCC13 and SCCO22 cells with CSL 
gene silencing, with DAPI staining for cell 
identification. Shown are representative images 
of HKC staining (left panel) and quantification 
of fluorescence signal using ImageJ software 
from all tested cell lines (right panel). Data are 
shown as mean ± SEM, 2-tailed 1-sample t test. 
Scale bars: 150 μm. (D) The same RNA samples 
as in Figure 8C were examined by RT-qPCR for 
KDM6B expression. Data are shown as mean 
± SEM, 1-tailed 1-sample t test. n = 4 mice for 
SCC13 at week 1; n = 5 mice for SCC13 at week 2; 
n = 5 mice for SCCO28 at week 1; n = 4 mice for 
SCCO28 at week 2. (E) LCM-obtained epidermis 
from AK and skin SCC lesions versus flank-
ing normal skin were analyzed by RT-qPCR 
for KDM6B expression. P, patients. n = 6 AK 
regions; n = 6 normal regions; n = 2 SCC regions; 
n = 2 normal regions. (A–E) *P < 0.05; **P < 
0.005; ***P < 0.0005, 2-tailed paired t test.
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Tumorigenesis experiments. Intradermal ear-injection assays were 
carried out in 6- to 8-week-old NOD/SCID mice with IL-2 receptor 
γ chain null mutation (University of Lausanne). For in vivo silencing 
assays, SCC cells were infected with either control or shCSL viruses 
for 5 days and injected in equal number (2 × 105 cells per injection) 
into left and right ears of each mouse. For in vivo dual silencing assays, 
SCC cells were first infected with either control or shKDM6B retro-
viruses for 6 days, followed by infection with shCSL lentiviruses for 
5 days before injection into mouse ears (2 × 105 cells per injection). 
For in vivo overexpression assays, SCC cells were infected with either 
control or pIND20-mycCSL viruses and injected in equal number 
(2 × 105 cells per injection) into left and right ears of each mouse. 
Doxycycline (1 mg/ml) was freshly added to drinking water (contain-
ing 5% sucrose) every other day. In all cases, cells were concentrated 
ences), respectively. In brief, cells were harvested and incubated for 
30 minutes on ice using the Aqua Dead Cell Stain Kit (Thermo Fisher 
Scientific). Cells were then washed with annexin-binding buffer, fol-
lowed by incubation for 15 minutes at RT with annexin-Cy5 dye for 
staining of preapoptotic cells. Following annexin incubation, cell were 
fixed with 4% formaldehyde and counterstained with DAPI.
For gene expression, cells were collected for RNA followed by RT-
qPCR analysis. Total RNA (1 μg) was reverse-transcribed into cDNA 
using RevertAid H Minus Reverse Transcriptase (Thermo Scientific). 
Real-time qPCR was then done using SYBR Fast qPCR Master Mix 
(Kapa Biosystems) in Light Cycler 480 (Roche) according to the man-
ufacturer’s protocols. All RNA samples were analyzed in triplicate with 
gene-specific primers and 36B4 for normalization. The list of primers 
is provided in Supplemental Table 4.
Figure 11. KDM6B as a downstream CSL target counteracting its growth-enhancing modulatory function. (A) Three independent strains of HKCs stably 
infected with retroviral viruses expressing KDM6B, KDM6B demethylase-defective point mutant (H1390A), and empty vector control were tested for cell 
metabolic activity assays over the indicated days. Data are shown as mean ± SD. n = 3 biological replicates/strain. (B) The same HKC strains as in A were 
plated at a limited density, and colony formation was measured. Data are shown as mean ± SD. n = 3 biological replicates/strain. (C) SCC13 and SCCO22 
cells were infected with shRNA lentivirus against KDM6B or empty control, followed by infection with either control or CSL-silencing lentiviruses. Cells were 
tested for cell metabolic activity assays over the indicated days. Data are shown as mean ± SEM. n = 3 independent experiments. (D) The same cells as 
in C were plated at a limited density, and colony formation was measured. Data are shown as mean ± SEM. n = 3 independent experiments. (E) The same 
colony dishes as in D were assessed for the number of large colonies. (F) The same SCC13 cells as in C were analyzed by RT-qPCR for the indicated genes 
using 36B4 for normalization. Data are shown as mean ± SEM. Two-tailed unpaired t test, followed by Benjamini-Hochberg correction. n = 3 independent 
experiments. (A–E) *P < 0.1; **P < 0.01; ***P < 0.001, 1-way ANOVA with Tukey’s test.
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Figure 12. KDM6B as a downstream CSL target mediating its tumor-suppressive function. (A) SCC13, SCCO22, and SCCO28 cells freshly infected with 
shRNA lentiviruses against CSL or KDM6B individually or in combination, followed by parallel injection into ears of NOD/SCID mice. Shown are tumor 
volumes at day of sacrifice (upper panel) with representative images for 1 pair of mouse ears (lower panel) and corresponding H&E staining of SCCO22 
lesions (right panel). n = 5 mice for SCC13 lesions; n = 5 mice for SCCO22 lesions; n = 5 mice for SCCO28 lesions. Scale bars: 250 μm. (B) Double-immuno-
fluorescence analysis of proliferation (Ki67) and epithelial (pan-keratin) markers in ear lesions formed by SCCO22 cells. Shown are representative images 
as well as quantification of Ki67-positive nuclei in keratin-positive regions using ImageJ software. n = 5 mice. Scale bars: 150 μm. (C and D) Immunohis-
tochemical analysis of ear lesions formed by SCCO22 cells with antibodies against IL-6 and CD45. Shown are representative images as well as quantifica-
tion of positive regions using ImageJ software. n = 5 mice. Scale bars: 250 μm. (A–D) Data are shown as mean ± SEM. *P < 0.05; **P < 0.005;  
***P < 0.0005, 1-tailed paired t test.
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count data, estimate biological variance, and determine differential 
expression in HKC and SCC cell lines after CSL silencing, generating 
fold-changes and P values for each class comparison. DAVID software 
(https://david.ncifcrf.gov/) was used for GO analysis on lists of genes 
up- and downregulated upon CSL silencing. Lists of genes modulated 
and their corresponding GO are shown in Supplemental Table 1.
GSEA for RNA-seq expression profiles were performed using 
GSAA-SeqSP software (gene set association analysis for RNA-seq data 
with sample permutation) (79) from the Gene Set Association Analy-
sis (GSAA) platform (version GSAA_2.0, http://gsaa.unc.edu/). Curat-
ed gene sets were obtained from the Molecular Signatures Database 
(MSigDB v5.2; http://www.broadinstitute.org/gsea/msigdb/). Gene 
sets tested in this study are listed in Supplemental Table 2.
ChIP-seq and ChIP-tagmentation. ChIP assays with antibody 
against CSL versus nonimmune IgG control were performed as previ-
ously described (40), followed by assessment of fold enrichment for 
indicated sites. Primer sequences and antibodies used in this assay are 
listed in Supplemental Tables 4 and 5, respectively.
For ChIP-seq, DNA was immunoprecipitated from 5 × 106 HKCs 
using 10 μl CSL antibody per 106 cells, followed by quantification by 
fluorometry on a Qubit system (Invitrogen). A total of 10 ng DNA was 
used for library preparation using the NEBNext ChIP-Seq Library Prep 
Kit (Illumina) according to the manufacturer’s recommendations. 
FASTQ file alignments were done using the Burrows–Wheeler Aligner 
(http://bio-bwa.sourceforge.net), and peak detection was done using 
Model-Based Analysis for ChIP-Seq (MACS) software (http://liulab.
dfci.harvard.edu/MACS) with default parameters. For a graphic illus-
tration of ChIP-Seq peaks, the Integrative Genomics Viewer (IGV) 
(http://www.broadinstitute.org/igv) was used with Encyclopedia of 
DNA Elements (ENCODE) data (http://genome.ucsc.edu/ENCODE) 
for information on chromatin organization. The list of peaks is shown 
in Supplemental Table 3.
For ChIP-tagmentation, DNA was immunoprecipitated from 
1 × 106 HKCs using 10 μl CSL antibody per 106 cells. Chromatin was 
tagged with Tn5 transposase (Illumina), followed by decrosslinking, 
purification, and amplification (14 cycles) using tag-specific primers. 
Amplified products were diluted 10 times, and 1 μl was used for qPCR 
to determine fold enrichment at indicated sites.
Accession numbers. The RNA-seq and ChIP-seq data sets generat-
ed for this study were deposited in the NCBI’s Gene Expression Omni-
bus database (GEO GSE102762 and GSE102761).
Statistics. Data are presented as mean ± SD or mean ± SEM among 
controls and experimental groups, as indicated in the figure legends. 
Statistical significance between controls and experimental groups 
was assessed by Student’s t test (with Benjamini-Hochberg correction 
where needed) or 1-way ANOVA (with Dunnett’s or Tukey’s test), as 
indicated in the figure legends. *P < 0.05 was considered statistically 
significant (unless otherwise indicated).
Study approval. All mouse work was carried out according to Swiss 
guidelines for the use of laboratory animals, with protocols approved 
by the veterinary office of Canton de Vaud. All excised human samples 
were used with the approval of the University of Lausanne and CHUV. 
Informed consent was obtained as required.
Author contributions
DAL and SHJ performed experiments and contributed to the anal-
ysis of results. PO conducted bioinformatics analysis. CS, MB, and 
by centrifugation and resuspended in 3 μl of medium per ear injection 
using a 33-gauge microsyringe (Hamilton). Mice were sacrificed for 
tissue analysis 5 to 8 weeks later, after the injection.
Intradermal back-injection assays were carried out in 6- to 
8-week-old NOD/SCID mice with IL-2 receptor γ chain null muta-
tion (University of Lausanne). SCC cells were infected with the virus 
of interest, brought into suspension, and admixed with 70 μl Matrigel 
(BD Biosciences), followed by injection of equal numbers (106 cells per 
injection) into left and right sides of the mouse back. Mice were sacri-
ficed for tissue analysis 1 week and 2 weeks after injection.
Tumor size was measured using a digital caliper, and volume was 
calculated using the following formula: volume = length × width × height.
Immunodetection techniques. Conditions for immunoblotting, immu-
nofluorescence, and immunohistochemistry were as previously reported 
(74). The list of antibodies is provided in Supplemental Table 5. Scans of 
the full uncut immunoblots are shown in Supplemental Figure 5.
For immunofluorescence, cells were fixed with 4% paraformalde-
hyde and permeabilized in 0.1% Triton X-100, followed by blocking in 5% 
donkey serum in PBS. Primary antibodies were incubated at 4°C over-
night, followed by PBS washes, then incubated with secondary antibodies 
at RT for 1 hour and mounted in Fluoromount Mounting Medium (Mil-
liporeSigma) after nuclear DAPI staining. Immunofluorescence images 
were acquired with a Zeiss LSM700 Meta laser-scanning microscope.
For immunofluorescence-guided LCM, frozen tissues were 
freshly cut and immediately fixed with 75% ethanol for 30 seconds. 
Sections were then briefly blocked in 10% donkey serum in PBS for 
2 minutes, followed by incubation with Alexa Fluor 488–conjugated 
antibodies and propidium iodide (MilliporeSigma) for 2 minutes. Sec-
tions were washed by rinsing in PBS, then air-dried before processing 
using the Arcturus XT Microdissection System (Applied Biosystems).
For immunohistochemistry, cells were fixed with acetone for 
3 minutes, followed by blocking of endogenous peroxidase by per-
oxidase-blocking solution (3% H2O2 in PBS) for 10 minutes. Cells 
were further blocked in 10% goat serum in PBS for 10 minutes. Pri-
mary antibodies were incubated for 1 hour at RT, followed by PBS 
washes, then incubated with secondary antibodies for 30 minutes at 
RT. Cells were then incubated for 3 minutes with DAB solution, fol-
lowed by counterstaining for 4 seconds with Harris Haematoxylin 
(Leica Biosystems).
For signal quantification, acquired images for each color chan-
nel were imported into ImageJ software and converted into binary 
images. Intensity was measured using “measurement” or “particle 
analysis” in areas of interest. All measurements were exported as 
Microsoft Excel files.
RNA-seq and GSEA. RNA-seq analysis was performed as fol-
lows. Total RNA was extracted 5 days after shRNA infection for CSL- 
silencing cells using Direct-zol RNA Miniprep Kit (Zymo Research). 
Library preparation using TruSeq Kit (Illumina) was done with 4 μg of 
total RNA. Single read was done on an Illumina HiSeq 2000 sequencer 
at the Genomic Facility (University of Lausanne). Reads were trimmed 
by using Trimmomatic (v0.22; http://www.usadellab.org/cms/ 
?page=trimmomatic), followed by mapping to the human hg19 refer-
ence genome using TopHat (v2.0.8b; https://ccb.jhu.edu/software/ 
tophat/index.shtml). Gene-expression levels were then evaluated 
using the HTSeq package (release 0.5.4p1; https://htseq.readthedocs.
io/en/release_0.9.1/). The DeSeq2 package (https://bioconductor.org/
packages/release/bioc/html/DESeq2.html) was used to normalize 
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